178 related articles for article (PubMed ID: 23904233)
1. CD30-positive malignant lymphomas: time for a change of management?
Engert A
Haematologica; 2013 Aug; 98(8):1165-8. PubMed ID: 23904233
[No Abstract] [Full Text] [Related]
2. Anti-CD30 Antibodies for Hodgkin lymphoma.
Foyil KV; Bartlett NL
Curr Hematol Malig Rep; 2010 Jul; 5(3):140-7. PubMed ID: 20446121
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin for CD30-positive tumours.
Masuda S; Miyagawa S; Nakamura T; Khurram MA; Sawa Y
Lancet Oncol; 2016 Sep; 17(9):e371. PubMed ID: 27599139
[No Abstract] [Full Text] [Related]
4. Brentuximab vedotin.
Younes A; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2012 Jan; 11(1):19-20. PubMed ID: 22212672
[No Abstract] [Full Text] [Related]
5. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Bhatt G; Maddocks K; Christian B
Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
[TBL] [Abstract][Full Text] [Related]
6. CD30: from basic research to cancer therapy.
Muta H; Podack ER
Immunol Res; 2013 Dec; 57(1-3):151-8. PubMed ID: 24233555
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
Scott LJ
Drugs; 2017 Mar; 77(4):435-445. PubMed ID: 28190142
[TBL] [Abstract][Full Text] [Related]
8. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.
Blatt K; Cerny-Reiterer S; Schwaab J; Sotlar K; Eisenwort G; Stefanzl G; Hoermann G; Mayerhofer M; Schneeweiss M; Knapp S; Rülicke T; Hadzijusufovic E; Bauer K; Smiljkovic D; Willmann M; Reiter A; Horny HP; Valent P
Blood; 2015 Dec; 126(26):2832-41. PubMed ID: 26486787
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin.
Ansell SM
Blood; 2014 Nov; 124(22):3197-200. PubMed ID: 25293772
[TBL] [Abstract][Full Text] [Related]
10. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?
Goyal SD; Bartlett NL
Curr Hematol Malig Rep; 2012 Sep; 7(3):179-85. PubMed ID: 22669711
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab in the treatment of CD30-positive enteropathy-associated T-cell lymphoma.
Khalaf WF; Caldwell ME; Reddy N
J Natl Compr Canc Netw; 2013 Feb; 11(2):137-40; quiz 140. PubMed ID: 23411380
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.
Kim M; Lee JO; Koh J; Kim TM; Lee JY; Jeon YK; Keam B; Kim DW; Lee JS; Heo DS
Haematologica; 2021 Aug; 106(8):2277-2280. PubMed ID: 33792222
[No Abstract] [Full Text] [Related]
14. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
15. [Advances in the treatment of CD30 positive lymphoma with brentuximab vedotin].
Cai MC; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):81-86. PubMed ID: 36987732
[No Abstract] [Full Text] [Related]
16. CD30 as a therapeutic target in adult haematological malignancies: Where are we now?
Veyri M; Spano JP; Le Bras F; Marcelin AG; Todesco E
Br J Haematol; 2023 Jun; 201(6):1033-1046. PubMed ID: 37170397
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.
Zhao B; Chen R; O'Connor OA; Gopal AK; Ramchandren R; Goy A; Matous JV; Fasanmade AA; Manley TJ; Han TH
Br J Clin Pharmacol; 2016 Sep; 82(3):696-705. PubMed ID: 27115790
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
[TBL] [Abstract][Full Text] [Related]
19. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure.
Nathwani N; Krishnan AY; Huang Q; Kim Y; Karanes C; Smith EP; Forman SJ; Sievers E; Thomas SH; Chen RW
Leuk Lymphoma; 2012 Oct; 53(10):2051-3. PubMed ID: 22369501
[No Abstract] [Full Text] [Related]
20. Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma.
Wang CC; Thanh C; Gibson EA; Ball-Burack M; Hogan LE; Descours B; Jones N; Carvidi AB; Munter S; Bakkour S; Busch MP; Milush JM; Deeks SG; Henrich TJ
Blood Adv; 2018 Dec; 2(23):3479-3482. PubMed ID: 30530753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
